25 March 2022 in Blood Advances
The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Fludarabine exposure, previously shown to be highly variable when dosing is based on body surface area (BSA), is a predictor for survival in allogeneic hematopoietic cell transplantation (allo-HCT). Hence, we hypothesized that an optimal exposure of fludarabine might be of clinical importance in CD19 CAR T-cell treatment. We examined the effect of cumulative fludarabine exposure during lymphodepletion, defined as concentration-time curve (AUC), on clinical outcome and lymphocyte kinetics. A retrospective analysis was conducted with data from 26 patients receiving tisagenlecleucel for r/r B-ALL. Exposure of fludarabine was shown to be a predictor for leukemia-free survival (LFS), B-cell aplasia, and CD19-positive relapse following CAR T-cell infusion. Minimal event probability was observed at a cumulative fludarabine AUCT0−∞ ≥14 mg*h/L, and underexposure was defined as an AUCT0−∞ <14 mg*h/L. In the underexposed group, the median LFS was 1.8 months, and the occurrence of CD19-positive relapse within 1 year was 100%, which was higher compared with the group with an AUCT0−∞ ≥14 mg*h/L (12.9 months; P < .001; and 27.4%; P = .0001, respectively). Furthermore, the duration of B-cell aplasia within 6 months was shorter in the underexposed group (77.3% vs 37.3%; P = .009). These results suggest that optimizing fludarabine exposure may have a relevant impact on LFS following CAR T-cell therapy, which needs to be validated in a prospective clinical trial.
11 June 2022 in Bone Marrow Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with a variety of malignant and non-malignant diseases. Despite its life-saving potential, HCT is associated with significant morbidity and mortality. Reciprocal interactions between hematopoietic stem cells (HSCs) and their surrounding bone marrow (BM) niche regulate HSC function during homeostatic hematopoiesis as well as regeneration. However, current pre-HCT conditioning regimens, which consist of high-dose chemotherapy and/or irradiation, cause substantial short- and long-term toxicity to the BM niche. This damage may negatively affect HSC function, impair hematopoietic regeneration after HCT and predispose to HCT-related morbidity and mortality. In this review, we summarize current knowledge on the cellular composition of the human BM niche after HCT. We describe how pre-HCT conditioning affects the cell types in the niche, including endothelial cells, mesenchymal stromal cells, osteoblasts, adipocytes, and neurons. Finally, we discuss therapeutic strategies to prevent or repair conditioning-induced niche damage, which may promote hematopoietic recovery and improve HCT outcome.
28 November 2024 in Blood Neoplasia
• Loss of p53 confers resistance to CAR T therapy by impairing death receptor expression. • Modulation of death receptor expression may improve CAR T–mediated killing of TP53WT and TP53Mut BCP-ALL.
17 July 2024 in Blood Neoplasia
27 March 2026 in Bone Marrow Transplantation
WLWillemijn J. Klein Lebbink
Willemijn J. Klein Lebbink
+6
The non-infectious pulmonary complications idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans syndrome (BOS) are important causes of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). To identify risk factors for these complications, we retrospectively analyzed baseline characteristics and longitudinal data from 633 pediatric and young adult allo-HCT recipients. Risk factors for IPS included non-malignant diagnosis (HR 2.97; 95% CI 1.27–6.97; P = 0.01) and adenovirus reactivation (HR 2.75; 95% CI 1.24–6.14; P = 0.01). Conditioning with busulfan-cyclophosphamide ±melphalan (BuCy ±Mel) associated with increased IPS risk compared to busulfan-fludarabine ±clofarabine (HR 5.15; 95% CI 2.36–11.24; P < 0.001) and non-myeloablative regimens (HR 9.78; 95% CI 2.48–38.61; P = 0.001). BuCy ±Mel conditioning also related to increased BOS risk relative to total body irradiation (TBI)(HR 5.11; 95%CI 1.65–15.83; P = 0.005) and non-myeloablative regimens (HR 19.68; 95% CI 2.53–155.76; P = 0.005). Moreover, elevated endothelial activation and stress index (EASIX), white blood cell, and lymphocyte counts before day 100 post-transplant correlated with IPS. For BOS, high EASIX and increased activated or effector memory CD4 + T-cells were additional significant correlates. In conclusion, IPS and BOS were associated with both distinct and overlapping risk factors in this study. These findings may inform future strategies to identify high-risk patients and develop targeted preventive interventions.
22 September 2025 in Research Square
WLWillemijn Klein Lebbink
+6
The non-infectious pulmonary complications idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans syndrome (BOS) are important causes of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). To identifying risk factors for these complications, we retrospectively analyzed baseline characteristics and longitudinal data from 633 pediatric and young adult allo-HCT recipients. Risk factors for IPS included non-malignant diagnosis (HR 2.97; 95% CI 1.27–6.97; P=0.01) and adenovirus reactivation (HR 2.75; 95% CI 1.24–6.14; P=0.01). Conditioning with busulfan-cyclophosphamide ±melphalan (BuCy ±Mel) associated with increased IPS risk compared to busulfan-fludarabine ±clofarabine (HR 5.15; 95% CI 2.36–11.24; P<0.001) and non-myeloablative regimens (HR 9.78; 95% CI 2.48–38.61; P=0.001). BuCy ±Mel conditioning also related to increased BOS risk relative to total body irradiation (TBI)(HR 5.11; 95%CI 1.65–15.83; P=0.005) and non-myeloablative regimens (HR 19.68; 95% CI 2.53–155.76; P=0.005). Moreover, elevated endothelial activation and stress index (EASIX), white blood cell, and lymphocyte counts before day 100 post-transplant correlated with IPS. For BOS, high EASIX and increased activated or effector memory CD4+ T-cells were additional significant correlates. In conclusion, IPS and BOS were associated with both distinct and overlapping risk factors in this study. These findings may inform future strategies to identify high-risk patients and develop targeted preventive interventions.